US SEC Trading Suspension Halt Orders — June 11, 2026

Nasdaq delisting confirmed effective June 16, 2026, following Chapter 11 filing on June 7, 2026; no appeal planned, signaling zero management confidence in equity recovery

Company explicitly warns existing equity holders face 'substantial risks' and 'limited recovery' under the prepackaged reorganization plan, effectively valuing equity at near-zero

Prior non-compliance with Nasdaq Rule 5550(b)(2) (min $35M market value) since March 18, 2026, was a leading indicator of the eventual delisting and bankruptcy

Potential OTC trading after delisting carries extreme risks including low liquidity, wider spreads, and potential for further price declines, offering no safe haven for holders

The bankruptcy filing and delisting occurred within 9 days of each other (June 7 to June 16), indicating a rapid and disorderly collapse of the company's public market status

No insider buying or capital allocation actions (dividends, buybacks) were reported, consistent with a company in terminal decline with no shareholder value preservation efforts

Chapter 11 filing on June 7, 2026, with a prepackaged plan that likely wipes out existing equity holders, representing a total loss scenario for common stock investors

Nasdaq suspension effective June 16, 2026, removes the primary trading venue, forcing shareholders into illiquid OTC markets with no guarantee of continued trading

Nasdaq's delisting determination explicitly cited 'public interest concerns' from the Chapter 11 filing, adding regulatory stigma that may deter future investment

No appeal of the delisting determination indicates management has abandoned efforts to preserve any equity value, signaling a complete lack of fiduciary action for shareholders

Post-delisting OTC trading will likely suffer from extreme illiquidity, making it nearly impossible for remaining holders to exit positions without severe price concessions

The prepackaged reorganization plan explicitly warns of 'limited recovery' for existing equity holders, with debt holders and other creditors likely receiving all value

Prior to the suspension date (June 16), any remaining liquidity could allow for short selling to capture near-total equity value destruction, though risk of a squeeze is minimal given the bankruptcy

For distressed debt investors, the prepackaged Chapter 11 plan may offer opportunities to acquire GoHealth's debt at a discount, potentially receiving equity or cash in the reorganized entity

If the reorganized company emerges from Chapter 11 with a cleaner balance sheet, new equity issued under the plan could represent a speculative turnaround play, though timing and terms are uncertain

The collapse provides a cautionary tale for investors in other micro-cap health insurance technology companies with high debt loads and low market capitalizations, potentially creating short opportunities in similar names

The speed of delisting (9 days from bankruptcy filing) may signal a more aggressive stance by Nasdaq on public interest concerns, which could be used to anticipate similar actions against other bankrupt companies

GoHealth's bankruptcy and delisting highlight the fragility of health insurance technology intermediaries that rely on commission-based revenue and have high fixed costs, especially when facing regulatory or reimbursement headwinds

The 9-day gap between bankruptcy filing and delisting announcement suggests Nasdaq is tightening its enforcement of public interest standards, potentially accelerating the timeline for other bankrupt companies to lose their listings

The complete destruction of equity value in GoHealth (from a once-public company to near-zero recovery) underscores the binary risk in micro-cap stocks with weak balance sheets and no path to profitability

GoHealth's use of a prepackaged Chapter 11 plan indicates a strategic decision to minimize court time and creditor negotiations, but it also signals that management had been planning for this outcome for months, likely to the detriment of equity holders

Monitor if and when GOCO begins trading on OTC markets post-June 16; extreme price volatility and potential for complete cessation of trading are key risks [Date: June 16, 2026+]

Watch for court approval of the prepackaged reorganization plan, which will determine the exact recovery (if any) for equity holders and the terms for any new equity issuance [Date: TBD]

Any insider buying or selling of GoHealth debt or post-bankruptcy equity could signal management's view on the reorganized company's prospects [Date: Ongoing]

Monitor other micro-cap health insurance tech firms (e.g., SelectQuote, eHealth) for similar signs of financial distress, such as Nasdaq non-compliance notices or debt covenant violations [Date: Ongoing]

Watch for any 8-K or 15-12G filings related to the termination of SEC reporting obligations, which would further reduce transparency and investor protections [Date: TBD]

Although the company stated it does not plan to appeal, any change in this decision before the suspension date could create a temporary reprieve or trading opportunity [Date: June 16, 2026]